# Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

> **NCT00759109** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 150 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b
- **OTHER:** Observation (no treatment)

## Key facts

- **NCT ID:** NCT00759109
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759109, "Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00759109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*